OB Pharmaceuticals has been granted utility patent US 10,087,138
posted in: Uncategorized 0
LONDON, ONTARIO October 2, 2018 — OB Pharmaceuticals has been granted utility patent US 10,087,138 from the U.S. Patent and … Read More
Dr. Michael Poulter, CSO of OB Pharmaceuticals to present at Eilat XIV.
posted in: Eilat XIV, Michael Poulter, Uncategorized 0
LONDON, ONTARIO May 2, 2018 — OB Pharmaceuticals was invited to present the details of its drug development program of … Read More
Dr. Larry Mahan, VP Business Development to present at Biotech Showcase 2018
posted in: Biotech Showcase, Larry Mahan, Uncategorized 0
LONDON, ONTARIO January 2, 2018 — Dr. Larry Mahan attended BioTech Showcase 2018 during JP Morgan week in San Francisco … Read More
OB Pharmaceuticals to attend BioEurope Spring 2017
posted in: BioEurope, Uncategorized 0
LONDON, ONTARIO March 10, 2017 — Representatives from OB Pharmaceuticals attended BioEurope Spring 2017 in Barcelona, Spain, March 20-22 to … Read More